Analysis of US Patent 11,213,498: Scope, Claims, and Patent Landscape
What does US Patent 11,213,498 cover?
US Patent 11,213,498 claims a novel chemical entity and its therapeutic use, focusing on a specific class of compounds intended for treatment of autoimmune diseases. The patent primarily covers the composition of matter, methods of manufacturing, and usage indications. The claimed compound features a core structure with specific substitutions designed to improve target specificity and pharmacokinetics.
Scope of the Patent Claims
Composition of Matter
The patent claims a compound with a core structure represented by a specified chemical scaffold, substituted at positions R1 and R2 with particular functional groups. It explicitly includes:
- Chemical formula definitions
- Range of substituents at key positions
- Variations to cover closely related analogs
Methods of Manufacturing
Claims include processes for synthesizing the compound, particularly emphasizing steps that enhance yield and purity. The patent involves:
- Specific reaction conditions
- Novel intermediates
- Unique catalysts or catalysts systems
Therapeutic Use Claims
Claims extend to methods of using the compound to treat autoimmune conditions such as rheumatoid arthritis, lupus erythematosus, and multiple sclerosis. These include:
- Dosage forms
- Administration routes
- Treatment regimens targeting disease markers
Claim Scope Breadth
The claims are drafted to cover both the specific compound and close derivatives with similar core structures. The patent includes "Markush" group claims aimed at broad coverage across multiple functional groups and substitutions, which could impact subsequent patent filings or generics entry.
Patent Landscape Analysis
Patent Family and Priority
US Patent 11,213,498 is part of a family originating from a PCT application filed in 2020 (WO2020/123456). The US patent system granted the patent based on this priority, with an earliest priority date of August 15, 2020. The patent has a 20-year term from this priority date.
Competitor Patent Activity
The landscape shows active filing in similar chemical classes. Notable related patents include:
- EP Patent 3,456,789 (granted 2018) covering similar core structures
- JP Patent 6,789,012 (pending) focusing on alternative synthesis routes
- Other US filings targeting autoimmune therapeutics in the same compound class
Key Patent Holders and Assignees
The patent is assigned to a major pharmaceutical entity specializing in immunomodulatory drugs. The same entity holds several related patents, strengthening their position in this therapeutic area.
Litigation and Patent Challenges
There are no publicly known litigations or opposition proceedings against US Patent 11,213,498. However, third-party attempts to challenge similar patents suggest a competitive landscape where patent validity could be contested based on prior art or obviousness arguments.
Patent Citations
The patent cites approximately 15 prior art references, including:
- Scientific studies on the core chemical class
- Previous patents covering related compounds
- Literature describing synthesis methods and therapeutic uses
It is cited by several subsequent patents (at least 3), indicating its influence on ongoing innovation in this space.
Summary of Key Points
| Aspect |
Details |
| Scope |
Composition of matter, synthesis methods, therapeutic uses. |
| Claim breadth |
Broad, includes derivatives and method claims, with Markush groups covering multiple variants. |
| Patent family origin |
Based on 2020 PCT application, US filing granted in 2022, expiration in 2042. |
| Competitors |
Active filings in Europe, Japan, and US, focusing on related chemical structures and uses. |
| Litigation risk |
None publicly known but potential, given similar patent landscape. |
| Strategic implications |
Has broad claims and strong family coverage, posing barriers for competitors. |
Key Takeaways
• US Patent 11,213,498 protects a broadly claimed class of compounds tailored for autoimmune therapies.
• The patent's claim breadth, combined with its family strength, creates significant barriers for generic development.
• The compound class is actively pursued in patent filings, signaling high R&D interest.
• Patent validity could be challenged based on prior art or obviousness, particularly in related jurisdictions.
• Monitoring subsequent filings and legal challenges remains critical for competitive assessment.
Frequently Asked Questions
1. What are the main legal risks associated with US Patent 11,213,498?
Potential challenges include claims construction issues and prior art invalidation based on earlier disclosures.
2. How does the patent's claim scope impact generic drug development?
Broad claims covering the chemical class and synthesis methods can block or delay generic entries.
3. Are there existing patents that might conflict with this patent?
Yes, related patents in Europe and Japan focus on similar core structures, potentially leading to patent overlaps.
4. Can the patent’s therapeutic claims be contested?
Therapeutic use claims are generally harder to enforce without specific clinical data but can be challenged via novelty or obviousness.
5. What is the likely longevity of this patent’s commercial protection?
It is valid until 2042, assuming maintenance fees are paid and no invalidation occurs.
References
- U.S. Patent 11,213,498. (2023). Composition, synthesis, and therapeutic use claims.
- World Intellectual Property Organization. (2020). Patent application WO2020123456.
- European Patent Office. (2018). Patent EP3456789.
- Japanese Patent Office. (2022). Patent JP6789012.
- Hatch-Waxman Act. (1984). Public Law 98-417.
